Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates
Name
Rifampicin
Accession Number
DB01045  (APRD00207, EXPT02777)
Type
Small Molecule
Groups
Approved
Description

A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)

Structure
Thumb
Synonyms
  • 3-(((4-Methyl-1-piperazinyl)imino)methyl)rifamycin SV
  • RFP
  • Rifampicin
  • Rifampicina
  • Rifampicine
  • Rifampicinum
  • Rifampin
External IDs
BA-41166/E / L-5103 LEPETIT / NIH-10782 / NSC-113926 / NSC-113926-
Product Ingredients
IngredientUNIICASInChI Key
Rifampicin sodiumGPE7477YEK38776-75-9PPGHYTPFGILTSZ-LGIBZRBQSA-M
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
RifadinCapsule150 mgOralSanofi Aventis1995-12-31Not applicableCanada
RifadinCapsule300 mgOralSanofi Aventis1995-12-31Not applicableCanada
RifadinCapsule300 mg/1OralPhysicians Total Care, Inc.1971-05-212010-06-30Us
RifadinCapsule300 mg/1Oralsanofi-aventis U.S. LLC1971-05-21Not applicableUs
RifadinCapsule150 mg/1Oralsanofi-aventis U.S. LLC1981-07-15Not applicableUs
Rifadin Cap 300mgCapsuleOralMerrell Dow Pharmaceuticals (Canada) Inc., Division Of Mmdc1988-12-311996-09-09Canada
Rifadin IVInjection, powder, lyophilized, for solution600 mg/10mLIntravenoussanofi-aventis U.S. LLC1989-05-25Not applicableUs
Rifadin IV NOVAPLUSInjection, powder, lyophilized, for solution600 mg/10mLIntravenoussanofi-aventis U.S. LLC2017-02-01Not applicableUs
RofactCapsuleOralBausch Health, Canada Inc.1977-12-31Not applicableCanada
RofactCapsuleOralBausch Health, Canada Inc.1977-12-31Not applicableCanada
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
RifampinInjection, powder, lyophilized, for solution600 mg/10mLIntravenousHeritage Pharmaceuticals Inc.2014-08-18Not applicableUs
RifampinInjection, powder, lyophilized, for solution600 mg/10mLIntravenousPfizer Laboratories Div Pfizer Inc.2011-05-102017-12-31Us
RifampinCapsule300 mg/1OralREMEDYREPACK INC.2019-11-05Not applicableUs
RifampinInjection, powder, lyophilized, for solution600 mg/10mLIntravenousVersa Pharm Incorporated2011-03-112013-09-16Us
RifampinCapsule300 mg/1OralREMEDYREPACK INC.2016-12-12Not applicableUs
RifampinCapsule, coated300 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs61748 0018 60 nlmimage10 7c3cbe75
RifampinInjection, powder, lyophilized, for solution600 mg/10mLIntravenousMylan Institutional LLC2015-01-21Not applicableUs
RifampinCapsule150 mg/1OralRemedy Repack2010-06-302010-06-30Us
RifampinCapsule300 mg/1Oralbryant ranch prepack1997-05-28Not applicableUs
RifampinCapsule, coated300 mg/1OralCarilion Materials Management2001-07-01Not applicableUs68151 098520180907 15195 1pviji6
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
IsonaRifRifampicin (300 mg/1) + Isoniazid (150 mg/1)CapsuleOralVersaPharm Incorporated2005-09-01Not applicableUs
RifamateRifampicin (300 mg/1) + Isoniazid (150 mg/1)CapsuleOralsanofi-aventis U.S. LLC1975-07-11Not applicableUs
RifaterRifampicin (120 mg/1) + Isoniazid (50 mg/1) + Pyrazinamide (300 mg/1)Tablet, sugar coatedOralRemedy Repack2010-09-152010-09-16Us
RifaterRifampicin (120 mg) + Isoniazid (50 mg) + Pyrazinamide (300 mg)TabletOralSanofi Aventis1995-12-312017-03-29Canada
RifaterRifampicin (120 mg/1) + Isoniazid (50 mg/1) + Pyrazinamide (300 mg/1)Tablet, sugar coatedOralsanofi-aventis U.S. LLC1994-05-31Not applicableUs
International/Other Brands
Rifadine / Rifaldin / Rifoldin / Rimactan / Rimactane / Rofact / Tubocin
Categories
UNII
VJT6J7R4TR
CAS number
13292-46-1
Weight
Average: 822.9402
Monoisotopic: 822.40512334
Chemical Formula
C43H58N4O12
InChI Key
JQXXHWHPUNPDRT-WLSIYKJHSA-N
InChI
InChI=1S/C43H58N4O12/c1-21-12-11-13-22(2)42(55)45-33-28(20-44-47-17-15-46(9)16-18-47)37(52)30-31(38(33)53)36(51)26(6)40-32(30)41(54)43(8,59-40)57-19-14-29(56-10)23(3)39(58-27(7)48)25(5)35(50)24(4)34(21)49/h11-14,19-21,23-25,29,34-35,39,49-53H,15-18H2,1-10H3,(H,45,55)/b12-11+,19-14+,22-13-,44-20+/t21-,23+,24+,25+,29-,34-,35+,39+,43-/m0/s1
IUPAC Name
(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(1E)-[(4-methylpiperazin-1-yl)imino]methyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.1⁴,⁷.0⁵,²⁸]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl acetate
SMILES
CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C

Pharmacology

Indication

For the treatment of Tuberculosis and Tuberculosis-related mycobacterial infections.

Associated Conditions
Pharmacodynamics

Rifampin is an antibiotic that inhibits DNA-dependent RNA polymerase activity in susceptible cells. Specifically, it interacts with bacterial RNA polymerase but does not inhibit the mammalian enzyme. It is bactericidal and has a very broad spectrum of activity against most gram-positive and gram-negative organisms (including Pseudomonas aeruginosa) and specifically Mycobacterium tuberculosis. Because of rapid emergence of resistant bacteria, use is restricted to treatment of mycobacterial infections and a few other indications. Rifampin is well absorbed when taken orally and is distributed widely in body tissues and fluids, including the CSF. It is metabolized in the liver and eliminated in bile and, to a much lesser extent, in urine, but dose adjustments are unnecessary with renal insufficiency.

Mechanism of action

Rifampin acts via the inhibition of DNA-dependent RNA polymerase, leading to a suppression of RNA synthesis and cell death.

TargetActionsOrganism
ADNA-directed RNA polymerase subunit beta
inhibitor
Escherichia coli (strain K12)
UNuclear receptor subfamily 1 group I member 2
agonist
Humans
Additional Data Available
Adverse Effects

Comprehensive structured data on known drug adverse effects with statistical prevalence. MedDRA and ICD10 ids are provided for adverse effect conditions and symptoms.

Learn more
Additional Data Available
Contraindications

Structured data covering drug contraindications. Each contraindication describes a scenario in which the drug is not to be used. Includes restrictions on co-administration, contraindicated populations, and more.

Learn more
Additional Data Available
Blackbox Warnings

Structured data representing warnings from the black box section of drug labels. These warnings cover important and dangerous risks, contraindications, or adverse effects.

Learn more
Absorption

Well absorbed from gastrointestinal tract.

Volume of distribution
Not Available
Protein binding

89%

Metabolism

Primarily hepatic, rapidly deacetylated.

Route of elimination

Less than 30% of the dose is excreted in the urine as rifampin or metabolites.

Half life

3.35 (+/- 0.66) hours

Clearance
  • 0.19 +/- 0.06 L/hr/kg [300 mg IV]
  • 0.14 +/- 0.03 L/hr/kg [600 mg IV]
Toxicity

LD50=1570 mg/kg (rat), chronic exposure may cause nausea and vomiting and unconsciousness

Affected organisms
  • Mycobacteria
  • Mycobacterium tuberculosis
  • Various gram-negative and gram-positive eubacteria
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
(R)-warfarinThe metabolism of (R)-warfarin can be increased when combined with Rifampicin.
(S)-WarfarinThe metabolism of (S)-Warfarin can be increased when combined with Rifampicin.
4-hydroxycoumarinThe metabolism of 4-hydroxycoumarin can be increased when combined with Rifampicin.
6-O-benzylguanineThe metabolism of 6-O-benzylguanine can be increased when combined with Rifampicin.
8-azaguanineThe metabolism of 8-azaguanine can be increased when combined with Rifampicin.
8-chlorotheophyllineThe metabolism of 8-chlorotheophylline can be increased when combined with Rifampicin.
9-aminocamptothecinThe metabolism of Rifampicin can be increased when combined with 9-aminocamptothecin.
9-DeazaguanineThe metabolism of 9-Deazaguanine can be increased when combined with Rifampicin.
9-MethylguanineThe metabolism of 9-Methylguanine can be increased when combined with Rifampicin.
AbacavirThe metabolism of Abacavir can be increased when combined with Rifampicin.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
  • Avoid alcohol.
  • Take on empty stomach: 1 hour before or 2 hours after meals.
  • Take with a full glass of water.

References

Synthesis Reference

Klaus Jurgen, Joachim Seydel, "Combination preparations containing rifampicin and thioacetazon." U.S. Patent US5104875, issued August, 1973.

US5104875
General References
  1. Baysarowich J, Koteva K, Hughes DW, Ejim L, Griffiths E, Zhang K, Junop M, Wright GD: Rifamycin antibiotic resistance by ADP-ribosylation: Structure and diversity of Arr. Proc Natl Acad Sci U S A. 2008 Mar 25;105(12):4886-91. doi: 10.1073/pnas.0711939105. Epub 2008 Mar 18. [PubMed:18349144]
External Links
Human Metabolome Database
HMDB15179
KEGG Drug
D00211
KEGG Compound
C06688
PubChem Compound
5381226
PubChem Substance
46506170
ChemSpider
10468813
BindingDB
50370232
ChEBI
71365
ChEMBL
CHEMBL374478
Therapeutic Targets Database
DNC000965
PharmGKB
PA451250
Guide to Pharmacology
GtP Drug Page
HET
RFP
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Rifampin
ATC Codes
J04AM02 — Rifampicin and isoniazidJ04AB02 — RifampicinJ04AM06 — Rifampicin, pyrazinamide, ethambutol and isoniazidJ04AM05 — Rifampicin, pyrazinamide and isoniazidJ04AM07 — Rifampicin, ethambutol and isoniazid
AHFS Codes
  • 08:16.04 — Antituberculosis Agents
PDB Entries
1i6v / 1skx / 1ynn / 2hw2 / 3aob / 3aod / 4kmu / 5hv1 / 5kox / 5uac
show 10 more
FDA label
Download (43.3 KB)
MSDS
Download (86.7 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0CompletedTreatmentDrug Drug Interaction (DDI) / Pharmacokinetics1
0Not Yet RecruitingTreatmentRhinoscleroma1
0RecruitingTreatmentOsteomyelitis1
1Active Not RecruitingNot AvailableHealthy Volunteers1
1Active Not RecruitingOtherLung Cancer Non-Small Cell Cancer (NSCLC)1
1Active Not RecruitingOtherNeoplasms, Advanced Solid1
1Active Not RecruitingTreatmentAdvanced Malignancies (Except Leukemia) / Advanced Malignancies Except Leukemia / Non-Small Cell Lung Cancer (ALK-positive) / Non-Small Cell Lung Cancer (c-Met Dependent) / Non-Small Cell Lung Cancer (ROS Marker Positive) / Non-Small Cell Lung Cancer ALK-positive / Non-Small Cell Lung Cancer c-Met Dependent / Non-Small Cell Lung Cancer ROS Marker Positive / Systemic Anaplastic Large-Cell Lymphoma1
1CompletedNot AvailableHealthy Volunteers10
1CompletedNot AvailableHealthy Volunteers / Pharmacokinetics of Darexaban and Metabolites1
1CompletedNot AvailableHypertension,Essential1
1CompletedNot AvailableMetabolic Detoxication, Phase I1
1CompletedNot AvailablePharmacokinetics of YM1781
1CompletedNot AvailableTumors, Solid1
1CompletedBasic ScienceAdvanced Solid Tumors1
1CompletedBasic ScienceAlzheimer's Disease (AD)1
1CompletedBasic ScienceAtherothrombotic Diseases1
1CompletedBasic ScienceAutoimmune Diseases / Drug Drug Interaction (DDI) / Fibrotic Disease1
1CompletedBasic ScienceCoronary Artery Disease1
1CompletedBasic ScienceDiabetes Mellitus (DM)1
1CompletedBasic ScienceDrug Drug Interaction (DDI)1
1CompletedBasic ScienceDrug Drug Interaction (DDI) / Healthy Volunteers / Pharmacokinetics of Enzalutamide1
1CompletedBasic ScienceDrug Induced Constipation1
1CompletedBasic ScienceDrug Interaction Potentiation2
1CompletedBasic ScienceEndometriosis1
1CompletedBasic ScienceEvaluation of Pharmacokinetics of Sativex in the Absence and Presence of a CYP2C19 Inhibitor / Evaluation of Pharmacokinetics of Sativex in the Absence and Presence of a Known Inducer of CYP3A4 / Evaluation of Pharmacokinetics of Sativex in the Absence and Presence of a Potent Inhibitor of CYP3A41
1CompletedBasic ScienceGastrointestinal Hormones1
1CompletedBasic ScienceHealthy Volunteers10
1CompletedBasic ScienceHealthy Volunteers: Asian, Non-Asian1
1CompletedBasic ScienceHealthy Volunteers / Rheumatoid Arthritis1
1CompletedBasic ScienceInfections, Respiratory Syncytial Virus1
1CompletedBasic ScienceNASH - Nonalcoholic Steatohepatitis1
1CompletedBasic ScienceNeoplasms1
1CompletedBasic ScienceParkinson's Disease (PD)1
1CompletedBasic ScienceTumors, Solid1
1CompletedBasic ScienceThrombotic events1
1CompletedDiagnosticLung Function / Sarcoidosis, Pulmonary1
1CompletedHealth Services ResearchHuman Immunodeficiency Virus (HIV)1
1CompletedOtherAdverse Drug Interactions1
1CompletedOtherBiological Availability2
1CompletedOtherHealthy Volunteers8
1CompletedOtherMalignancies Multiple1
1CompletedOtherMalignancies, Hematologic / Malignant Lymphomas1
1CompletedOtherOncology, Medical1
1CompletedOtherTuberculosis Infection2
1CompletedTreatmentAdult Solid Neoplasm1
1CompletedTreatmentAdvanced Solid Tumors1
1CompletedTreatmentAdvanced Solid Tumors / Neoplasms1
1CompletedTreatmentAnaesthesia therapy / Sedation1
1CompletedTreatmentAnaplastic Large-Cell Lymphoma / Lymphoma, Hodgkins1
1CompletedTreatmentCarcinoma NOS / Hodgkins Disease (HD) / Lymphoma, Large-Cell, Anaplastic / Neoplasms / Non-Hodgkin's Lymphoma (NHL)1
1CompletedTreatmentChemotherapy-Induced Nausea and Vomiting (CINV) / Vomiting1
1CompletedTreatmentCystic Fibrosis (CF)2
1CompletedTreatmentDrug Drug Interaction (DDI)2
1CompletedTreatmentHealthy Male Volunteers1
1CompletedTreatmentHealthy Volunteers27
1CompletedTreatmentHepatitis C Viral Infection / Hepatitis C Virus (HCV) Infection / Pharmacokinetics / Rifampin / Tuberculosis Infection1
1CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections1
1CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Opioid Dependency1
1CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Tuberculosis Infection1
1CompletedTreatmentHuman Immunodeficiency Virus (HIV) / Tuberculosis Infection1
1CompletedTreatmentInfections, Respiratory Syncytial Virus1
1CompletedTreatmentLymphoma, Including Chronic Lymphocytic Leukemia / Tumors, Solid1
1CompletedTreatmentMalignancies1
1CompletedTreatmentMalignant Lymphomas / Nonhematologic Malignancies1
1CompletedTreatmentMalignant Lymphomas / Tumors, Solid1
1CompletedTreatmentMalignant Melanoma, Neoplasms1
1CompletedTreatmentMetastatic Melanoma, BRAF V600 Mutation Positive1
1CompletedTreatmentMultiple Myeloma (MM) / Non-Hodgkin's Lymphoma (NHL)1
1CompletedTreatmentNeoplasms1
1CompletedTreatmentNocturia1
1CompletedTreatmentParkinson's Disease (PD)1
1CompletedTreatmentPharmacokinetics1
1CompletedTreatmentPulmonary Tuberculosis (TB) / Tuberculosis Infection1
1CompletedTreatmentSystemic Infections1
1CompletedTreatmentTuberculosis Infection7
1CompletedTreatmentTumors1
1CompletedTreatmentType 2 Diabetes Mellitus1
1CompletedTreatmentImpaired kidney function1
1Not Yet RecruitingOtherLung Cancer Non-Small Cell Cancer (NSCLC)1
1Not Yet RecruitingTreatmentHIV-1-infection1
1Not Yet RecruitingTreatmentHIV-1-infection / Tuberculosis Infection1
1Not Yet RecruitingTreatmentHealthy Male Subjects1
1Not Yet RecruitingTreatmentHepatitis B Chronic Infection1
1RecruitingBasic ScienceTumors, Solid2
1RecruitingOtherHealthy Volunteers1
1RecruitingTreatmentHealthy Volunteers1
1RecruitingTreatmentHuman Immunodeficiency Virus (HIV)1
1RecruitingTreatmentIdiopathic Infantile Hypercalcemia - Mild Form1
1RecruitingTreatmentInfections, Fungal1
1SuspendedTreatmentTuberculosis Infection1
1TerminatedNot AvailableType 2 Diabetes Mellitus1
1TerminatedBasic ScienceInfection1
1TerminatedTreatmentHuman Immunodeficiency Virus (HIV) Infections1
1WithdrawnBasic ScienceHealthy Volunteers1
1WithdrawnBasic ScienceNon-Hodgkin's Lymphoma (NHL)1
1WithdrawnBasic SciencePulmonary Arterial Hypertension (PAH)1
1WithdrawnTreatmentMalignancies1
1, 2CompletedDiagnosticHealthy Volunteers1
1, 2CompletedDiagnosticSarcoidosis1
1, 2RecruitingTreatmentOther Specified Pulmonary Tuberculosis / Pulmonary Tuberculoses1
1, 2RecruitingTreatmentTuberculous Meningitis1
2CompletedBasic ScienceChronic Kidney Disease (CKD) / Tuberculosis Infection1
2CompletedTreatmentCystic Fibrosis (CF)1
2CompletedTreatmentCystic Fibrosis (CF) / Methicillin-Resistant Staphylococcus Aureus (MRSA)1
2CompletedTreatmentDisseminated Sclerosis1
2CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Infection, Mycobacterium Avium-Intracellulare1
2CompletedTreatmentInfection, Mycobacterium Avium-Intracellulare1
2CompletedTreatmentOnchocerciasis1
2CompletedTreatmentPulmonary Tuberculosis (TB)5
2CompletedTreatmentSarcoidosis; Antimycobacterial Therapy1
2CompletedTreatmentSmear Positive, Pan-sensitive, Pulmonary Tuberculosis1
2CompletedTreatmentTuberculosis Infection7
2CompletedTreatmentTuberculous Meningitis1
2Not Yet RecruitingTreatmentPulmonary Tuberculosis (TB) / Tuberculosis Infection1
2RecruitingTreatmentGenetic Diseases / Hypercalcemia, Idiopathic, of Infancy / Hypercalciuria / Hypercalciuric Hypercalcemia / Idiopathic Infantile Hypercalcaemia - Severe Form / Idiopathic Infantile Hypercalcemia - Mild Form1
2RecruitingTreatmentHIV-1-infection / Tuberculosis Meningitis1
2RecruitingTreatmentPulmonary Tuberculosis (TB)2
2RecruitingTreatmentPulmonary Tuberculosis (TB) / Tuberculosis Infection1
2RecruitingTreatmentTuberculosis Infection1
2RecruitingTreatmentLate phase Tuberculosis1
2TerminatedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Tuberculosis Infection1
2TerminatedTreatmentInfected Spacers / Prosthetic Joint Infections of Hip / Prosthetic Joint Infections of Knee1
2Unknown StatusTreatmentHip Prosthetic Joint Infection1
2Unknown StatusTreatmentPulmonary Tuberculosis (TB)1
2Unknown StatusTreatmentTuberculosis Infection1
2, 3CompletedTreatmentAcquired Immune Deficiency Syndrome (AIDS) / Human Immunodeficiency Virus (HIV) Infections / Tuberculosis Infection1
2, 3CompletedTreatmentTuberculous Meningitis1
2, 3Not Yet RecruitingTreatmentLate phase Tuberculosis1
2, 3RecruitingTreatmentDrug-resistant Tuberculosis / Extensively Drug Resistant Tuberculosis / Multi-Drug Resistant Tuberculosis / Pulmonary Tuberculosis (TB) / Tuberculosis Infection / Tuberculosis, Multidrug Resistant1
2, 3RecruitingTreatmentMycobacterium avium complex infection / Nontuberculous Mycobacterium Infection1
2, 3RecruitingTreatmentPulmonary Tuberculosis (TB)1
3CompletedPreventionHuman Immunodeficiency Virus (HIV) Infections / Tuberculosis Infection1
3CompletedTreatmentAcquired Immune Deficiency Syndrome (AIDS) / Human Immunodeficiency Virus (HIV) Infections / Tuberculosis Infection1
3CompletedTreatmentAlzheimer's Disease (AD)1
3CompletedTreatmentAntibiotic-Associated Diarrhea / Clostridium Enterocolitis / Pseudomembranous Colitis / Pseudomembranous Enteritis / Pseudomembranous Enterocolitis1
3CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Pulmonary Tuberculosis (TB)1
3CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Tuberculosis Infection1
3CompletedTreatmentHospital-acquired bacterial pneumonia / Infection Due to Resistant Bacteria / Infection of Bloodstream / Infectious Disease of Abdomen / Ventilator-Associated Pneumonia (VAP)1
3CompletedTreatmentLatent Tuberculosis Infection (LTI)2
3CompletedTreatmentPulmonary Multi-Drug Resistant Tuberculosis (MDR-TB) / Tuberculosis, Pulmonary, Drug Sensitive1
3CompletedTreatmentPulmonary Tuberculosis (TB)1
3CompletedTreatmentReactive Arthritis / Reiter's Disease1
3CompletedTreatmentTuberculosis Infection4
3Not Yet RecruitingTreatmentAnterior Uveitis (AU)1
3Not Yet RecruitingTreatmentPulmonary Tuberculosis (TB)1
3RecruitingPreventionHansen's Disease1
3RecruitingTreatmentInfective Endocarditis1
3RecruitingTreatmentLung Infection / Mycobacterium avium complex infection1
3RecruitingTreatmentPulmonary Tuberculosis (TB)1
3RecruitingTreatmentTuberculosis Infection1
3TerminatedTreatmentInfection1
3TerminatedTreatmentMultiple System Atrophy (MSA)1
3Unknown StatusPreventionLatent Tuberculosis Infection (LTI)1
3Unknown StatusTreatmentAlzheimer's Disease (AD)1
3Unknown StatusTreatmentDrug Safety1
3Unknown StatusTreatmentHuman Immunodeficiency Virus (HIV) Infections / Tuberculosis Infection1
3Unknown StatusTreatmentPulmonary Tuberculosis (TB)1
4Active Not RecruitingPreventionHuman Immunodeficiency Virus Type 1 (HIV-1) Infection1
4Active Not RecruitingTreatmentHuman Immunodeficiency Virus (HIV) Infections1
4CompletedNot AvailableStaphylococcus Aureus1
4CompletedBasic ScienceBlood Pressure Regulation1
4CompletedBasic ScienceGlucose Metabolism1
4CompletedBasic ScienceGlucose Tolerance1
4CompletedBasic ScienceHealthy Volunteers1
4CompletedBasic ScienceNon-Alcoholic Fatty Liver Disease (NAFLD)1
4CompletedDiagnosticDrug Drug Interaction (DDI) / Transplantation, Kidney1
4CompletedPreventionHuman Immunodeficiency Virus (HIV) Infections1
4CompletedPreventionHuman Immunodeficiency Virus (HIV) Infections / Tuberculosis Infection1
4CompletedTreatmentDiabetes Mellitus (DM)1
4CompletedTreatmentDiabetes Mellitus (DM) / Tuberculin (Skin Test) Positive1
4CompletedTreatmentDrug Induced Hepatotoxicity / Tuberculosis Infection1
4CompletedTreatmentHansen's Disease1
4CompletedTreatmentMRSA Infection1
4CompletedTreatmentPulmonary Diseases1
4Not Yet RecruitingTreatmentDrug Drug Interaction (DDI)1
4RecruitingBasic ScienceDrug Drug Interaction (DDI)1
4RecruitingTreatmentAIDS With Tuberculosis1
4RecruitingTreatmentAmputations / Diabetes Mellitus (DM) / Osteomyelitis1
4RecruitingTreatmentHuman Immunodeficiency Virus (HIV) Infections1
4RecruitingTreatmentOsteoarticular Infections1
4RecruitingTreatmentPulmonary Tuberculosis (TB)1
4RecruitingTreatmentTuberculosis, Spinal1
4SuspendedTreatmentCystic Fibrosis (CF) / MRSA1
4TerminatedTreatmentTuberculosis Infection1
4Unknown StatusTreatmentHepatitis / Pulmonary Tuberculosis (TB)1
4Unknown StatusTreatmentHuman Immunodeficiency Virus (HIV) Infections / Tuberculosis Infection1
4Unknown StatusTreatmentInfection caused by staphylococci / Prosthesis-Related Infections1
4Unknown StatusTreatmentReinfection Pulmonary Tuberculosis1
Not AvailableActive Not RecruitingBasic ScienceVitamin D and Calcium Homeostasis1
Not AvailableActive Not RecruitingTreatmentInfection caused by staphylococci1
Not AvailableActive Not RecruitingTreatmentMethicillin-Resistant Staphylococcus Aureus (MRSA)1
Not AvailableActive Not RecruitingTreatmentProsthetic Joint Infection1
Not AvailableCompletedNot AvailableHealthy Volunteers1
Not AvailableCompletedBasic ScienceDrug Drug Interaction (DDI) / Healthy Volunteers / Warfarin1
Not AvailableCompletedBasic ScienceHealthy Volunteers1
Not AvailableCompletedBasic ScienceHuman Immunodeficiency Virus (HIV) Infections1
Not AvailableCompletedDiagnosticCYP3A4 Induction1
Not AvailableCompletedPreventionHuman Immunodeficiency Virus (HIV) Infections / Tuberculosis Infection1
Not AvailableCompletedSupportive CareMotor Activities / Pulmonary Tuberculosis (TB) / Weight Changes1
Not AvailableCompletedTreatmentAcinetobacter Infections / Colistin / Rifampin1
Not AvailableCompletedTreatmentCystic Fibrosis (CF)1
Not AvailableCompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Tuberculosis Infection4
Not AvailableCompletedTreatmentOsteoarticular Infections1
Not AvailableCompletedTreatmentScrub Typhus1
Not AvailableCompletedTreatmentThroatcarriers of MRSA1
Not AvailableCompletedTreatmentTuberculosis Infection1
Not AvailableNot Yet RecruitingBasic ScienceHealthy Volunteers1
Not AvailableNot Yet RecruitingTreatmentPulmonary Tuberculosis (TB)1
Not AvailableRecruitingNot AvailableTuberculosis Infection1
Not AvailableRecruitingOtherHealthy Volunteers1
Not AvailableRecruitingPreventionMotility Disorders / Staphylococcus Aureus1
Not AvailableRecruitingTreatmentAcquired Immune Deficiency Syndrome (AIDS) / Pulmonary Tuberculosis (TB)1
Not AvailableRecruitingTreatmentDrug-resistant Tuberculosis / Tuberculosis Infection / Tuberculosis, Multidrug Resistant1
Not AvailableTerminatedNot AvailablePulmonary Tuberculosis (TB)1
Not AvailableUnknown StatusNot AvailablePulmonary Tuberculosis (TB)1
Not AvailableUnknown StatusTreatmentHidradenitis Suppurativa (HS)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
  • AAIPharma Inc.
  • Akorn Inc.
  • Amerisource Health Services Corp.
  • Apotheca Inc.
  • A-S Medication Solutions LLC
  • Bedford Labs
  • Belgomex Sprl
  • Ben Venue Laboratories Inc.
  • Cardinal Health
  • Ciba Geigy Ltd.
  • Comprehensive Consultant Services Inc.
  • Dept Health Central Pharmacy
  • Eon Labs
  • Gruppo Lepetit SPA
  • H.J. Harkins Co. Inc.
  • Innoviant Pharmacy Inc.
  • Lannett Co. Inc.
  • Major Pharmaceuticals
  • Mckesson Corp.
  • Medisca Inc.
  • Merrell Pharmaceuticals Inc.
  • Murfreesboro Pharmaceutical Nursing Supply
  • Novartis AG
  • Nucare Pharmaceuticals Inc.
  • PD-Rx Pharmaceuticals Inc.
  • Physicians Total Care Inc.
  • Rebel Distributors Corp.
  • Remedy Repack
  • Sanofi-Aventis Inc.
  • Spectrum Pharmaceuticals
  • Stat Rx Usa
  • Strides Arcolab Limited
  • Tya Pharmaceuticals
  • UDL Laboratories
  • Versapharm Inc.
  • West-Ward Pharmaceuticals
Dosage forms
FormRouteStrength
CapsuleOral50 mg/5mL
CapsuleOral150 mg
CapsuleOral300 mg
CapsuleOral
CapsuleOral150 mg/1
CapsuleOral300 mg/1
Capsule, coatedOral300 mg/1
Injection, powder, lyophilized, for solutionIntravenous600 mg/1
Injection, powder, lyophilized, for solutionIntravenous600 mg/10mL
TabletOral
Tablet, sugar coatedOral
CapsuleOral
Prices
Unit descriptionCostUnit
Rifadin iv 600 mg vial140.9USD vial
Rifampin iv 600 mg vial136.3USD vial
Rifampin crystals6.72USD g
Rifampin powder3.98USD g
Rifadin 300 mg capsule3.09USD capsule
Rifadin 150 mg capsule2.57USD capsule
Rifampin 300 mg capsule2.37USD capsule
Rimactane 300 mg capsule2.35USD capsule
Rifampin 150 mg capsule2.27USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)183 °CNot Available
water solubility1400 mg/L (at 25 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP2.7Not Available
pKa1.7SANGSTER (2004)
Predicted Properties
PropertyValueSource
Water Solubility0.0413 mg/mLALOGPS
logP3.85ALOGPS
logP2.77ChemAxon
logS-4.3ALOGPS
pKa (Strongest Acidic)6.9ChemAxon
pKa (Strongest Basic)7.53ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count14ChemAxon
Hydrogen Donor Count6ChemAxon
Polar Surface Area220.15 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity225.58 m3·mol-1ChemAxon
Polarizability86.46 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.5553
Blood Brain Barrier-0.974
Caco-2 permeable-0.7123
P-glycoprotein substrateSubstrate0.9308
P-glycoprotein inhibitor IInhibitor0.8564
P-glycoprotein inhibitor IINon-inhibitor0.6049
Renal organic cation transporterNon-inhibitor0.8178
CYP450 2C9 substrateNon-substrate0.8508
CYP450 2D6 substrateNon-substrate0.9115
CYP450 3A4 substrateSubstrate0.7296
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.8432
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9099
Ames testNon AMES toxic0.5803
CarcinogenicityNon-carcinogens0.8493
BiodegradationNot ready biodegradable0.9962
Rat acute toxicity2.6875 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.908
hERG inhibition (predictor II)Non-inhibitor0.5486
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as macrolactams. These are cyclic amides of amino carboxylic acids, having a 1-azacycloalkan-2-one structure, or analogues having unsaturation or heteroatoms replacing one or more carbon atoms of the ring. They are nitrogen analogues (the a nitrogen atom replacing the o atom of the cyclic carboxylic acid group ) of the naturally occurring macrolides.
Kingdom
Organic compounds
Super Class
Phenylpropanoids and polyketides
Class
Macrolactams
Sub Class
Not Available
Direct Parent
Macrolactams
Alternative Parents
Naphthofurans / Naphthols and derivatives / Benzofurans / Coumarans / Aryl alkyl ketones / Hydroquinones / Ketals / N-methylpiperazines / Amino acids and derivatives / Trialkylamines
show 13 more
Substituents
Macrolactam / Naphthofuran / 1-naphthol / Naphthalene / Benzofuran / Coumaran / Hydroquinone / Aryl alkyl ketone / Aryl ketone / Ketal
show 35 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
N-methylpiperazine, N-iminopiperazine, rifamycin (CHEBI:28077) / Ansamycins (C06688)

Targets

Kind
Protein
Organism
Escherichia coli (strain K12)
Pharmacological action
Yes
Actions
Inhibitor
General Function
Ribonucleoside binding
Specific Function
DNA-dependent RNA polymerase catalyzes the transcription of DNA into RNA using the four ribonucleoside triphosphates as substrates.
Gene Name
rpoB
Uniprot ID
P0A8V2
Uniprot Name
DNA-directed RNA polymerase subunit beta
Molecular Weight
150631.165 Da
References
  1. Villain-Guillot P, Bastide L, Gualtieri M, Leonetti JP: Progress in targeting bacterial transcription. Drug Discov Today. 2007 Mar;12(5-6):200-8. Epub 2007 Feb 5. [PubMed:17331884]
  2. White RJ, Lancini GC, Silvestri LG: Mechanism of action of rifampin on Mycobacterium smegmatis. J Bacteriol. 1971 Nov;108(2):737-41. [PubMed:4942761]
  3. Tupin A, Gualtieri M, Roquet-Baneres F, Morichaud Z, Brodolin K, Leonetti JP: Resistance to rifampicin: at the crossroads between ecological, genomic and medical concerns. Int J Antimicrob Agents. 2010 Jun;35(6):519-23. doi: 10.1016/j.ijantimicag.2009.12.017. Epub 2010 Feb 24. [PubMed:20185278]
  4. Campbell EA, Korzheva N, Mustaev A, Murakami K, Nair S, Goldfarb A, Darst SA: Structural mechanism for rifampicin inhibition of bacterial rna polymerase. Cell. 2001 Mar 23;104(6):901-12. [PubMed:11290327]
  5. Wehrli W: Rifampin: mechanisms of action and resistance. Rev Infect Dis. 1983 Jul-Aug;5 Suppl 3:S407-11. [PubMed:6356275]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Agonist
General Function
Zinc ion binding
Specific Function
Nuclear receptor that binds and is activated by variety of endogenous and xenobiotic compounds. Transcription factor that activates the transcription of multiple genes involved in the metabolism an...
Gene Name
NR1I2
Uniprot ID
O75469
Uniprot Name
Nuclear receptor subfamily 1 group I member 2
Molecular Weight
49761.245 Da
References
  1. Chen J, Raymond K: Roles of rifampicin in drug-drug interactions: underlying molecular mechanisms involving the nuclear pregnane X receptor. Ann Clin Microbiol Antimicrob. 2006 Feb 15;5:3. [PubMed:16480505]
  2. Cheng J, Ma X, Krausz KW, Idle JR, Gonzalez FJ: Rifampicin-activated human pregnane X receptor and CYP3A4 induction enhance acetaminophen-induced toxicity. Drug Metab Dispos. 2009 Aug;37(8):1611-21. doi: 10.1124/dmd.109.027565. Epub 2009 May 21. [PubMed:19460945]

Enzymes

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inducer
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  2. Dixit V, Hariparsad N, Li F, Desai P, Thummel KE, Unadkat JD: Cytochrome P450 enzymes and transporters induced by anti-human immunodeficiency virus protease inhibitors in human hepatocytes: implications for predicting clinical drug interactions. Drug Metab Dispos. 2007 Oct;35(10):1853-9. Epub 2007 Jul 16. [PubMed:17639026]
  3. Chen J, Raymond K: Roles of rifampicin in drug-drug interactions: underlying molecular mechanisms involving the nuclear pregnane X receptor. Ann Clin Microbiol Antimicrob. 2006 Feb 15;5:3. [PubMed:16480505]
  4. Clin-Info. (2006). In Compendium of Pharmaceuticals and Specialties: The Canadian Drug Reference for Health Professionals (pp. L57). Canadian Pharmacists Association. [ISBN:1-894402-22-7]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inducer
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Nassr N, Huennemeyer A, Herzog R, von Richter O, Hermann R, Koch M, Duffy K, Zech K, Lahu G: Effects of rifampicin on the pharmacokinetics of roflumilast and roflumilast N-oxide in healthy subjects. Br J Clin Pharmacol. 2009 Oct;68(4):580-7. doi: 10.1111/j.1365-2125.2009.03478.x. [PubMed:19843061]
  2. Backman JT, Granfors MT, Neuvonen PJ: Rifampicin is only a weak inducer of CYP1A2-mediated presystemic and systemic metabolism: studies with tizanidine and caffeine. Eur J Clin Pharmacol. 2006 Jun;62(6):451-61. doi: 10.1007/s00228-006-0127-x. Epub 2006 Apr 27. [PubMed:16758262]
  3. The Effect of Cytochrome P450 Metabolism on Drug Response, Interactions, and Adverse Effects [Link]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inducer
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C8
Uniprot ID
P10632
Uniprot Name
Cytochrome P450 2C8
Molecular Weight
55824.275 Da
References
  1. Dixit V, Hariparsad N, Li F, Desai P, Thummel KE, Unadkat JD: Cytochrome P450 enzymes and transporters induced by anti-human immunodeficiency virus protease inhibitors in human hepatocytes: implications for predicting clinical drug interactions. Drug Metab Dispos. 2007 Oct;35(10):1853-9. Epub 2007 Jul 16. [PubMed:17639026]
  2. Madan A, Graham RA, Carroll KM, Mudra DR, Burton LA, Krueger LA, Downey AD, Czerwinski M, Forster J, Ribadeneira MD, Gan LS, LeCluyse EL, Zech K, Robertson P Jr, Koch P, Antonian L, Wagner G, Yu L, Parkinson A: Effects of prototypical microsomal enzyme inducers on cytochrome P450 expression in cultured human hepatocytes. Drug Metab Dispos. 2003 Apr;31(4):421-31. [PubMed:12642468]
  3. Glaeser H, Drescher S, Eichelbaum M, Fromm MF: Influence of rifampicin on the expression and function of human intestinal cytochrome P450 enzymes. Br J Clin Pharmacol. 2005 Feb;59(2):199-206. doi: 10.1111/j.1365-2125.2004.02265.x. [PubMed:15676042]
  4. Gerbal-Chaloin S, Pascussi JM, Pichard-Garcia L, Daujat M, Waechter F, Fabre JM, Carrere N, Maurel P: Induction of CYP2C genes in human hepatocytes in primary culture. Drug Metab Dispos. 2001 Mar;29(3):242-51. [PubMed:11181490]
  5. Rae JM, Johnson MD, Lippman ME, Flockhart DA: Rifampin is a selective, pleiotropic inducer of drug metabolism genes in human hepatocytes: studies with cDNA and oligonucleotide expression arrays. J Pharmacol Exp Ther. 2001 Dec;299(3):849-57. [PubMed:11714868]
  6. Raucy JL, Mueller L, Duan K, Allen SW, Strom S, Lasker JM: Expression and induction of CYP2C P450 enzymes in primary cultures of human hepatocytes. J Pharmacol Exp Ther. 2002 Aug;302(2):475-82. doi: 10.1124/jpet.102.033837. [PubMed:12130704]
  7. Li AP, Reith MK, Rasmussen A, Gorski JC, Hall SD, Xu L, Kaminski DL, Cheng LK: Primary human hepatocytes as a tool for the evaluation of structure-activity relationship in cytochrome P450 induction potential of xenobiotics: evaluation of rifampin, rifapentine and rifabutin. Chem Biol Interact. 1997 Nov 6;107(1-2):17-30. [PubMed:9402947]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inducer
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Dixit V, Hariparsad N, Li F, Desai P, Thummel KE, Unadkat JD: Cytochrome P450 enzymes and transporters induced by anti-human immunodeficiency virus protease inhibitors in human hepatocytes: implications for predicting clinical drug interactions. Drug Metab Dispos. 2007 Oct;35(10):1853-9. Epub 2007 Jul 16. [PubMed:17639026]
  2. Edwards RJ, Price RJ, Watts PS, Renwick AB, Tredger JM, Boobis AR, Lake BG: Induction of cytochrome P450 enzymes in cultured precision-cut human liver slices. Drug Metab Dispos. 2003 Mar;31(3):282-8. [PubMed:12584154]
  3. Svensson EM, Murray S, Karlsson MO, Dooley KE: Rifampicin and rifapentine significantly reduce concentrations of bedaquiline, a new anti-TB drug. J Antimicrob Chemother. 2015 Apr;70(4):1106-14. doi: 10.1093/jac/dku504. Epub 2014 Dec 21. [PubMed:25535219]
  4. Clin-Info. (2006). In Compendium of Pharmaceuticals and Specialties: The Canadian Drug Reference for Health Professionals (pp. L57). Canadian Pharmacists Association. [ISBN:1-894402-22-7]
  5. FDA Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers [Link]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inducer
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2B6
Uniprot ID
P20813
Uniprot Name
Cytochrome P450 2B6
Molecular Weight
56277.81 Da
References
  1. Dixit V, Hariparsad N, Li F, Desai P, Thummel KE, Unadkat JD: Cytochrome P450 enzymes and transporters induced by anti-human immunodeficiency virus protease inhibitors in human hepatocytes: implications for predicting clinical drug interactions. Drug Metab Dispos. 2007 Oct;35(10):1853-9. Epub 2007 Jul 16. [PubMed:17639026]
  2. Loboz KK, Gross AS, Williams KM, Liauw WS, Day RO, Blievernicht JK, Zanger UM, McLachlan AJ: Cytochrome P450 2B6 activity as measured by bupropion hydroxylation: effect of induction by rifampin and ethnicity. Clin Pharmacol Ther. 2006 Jul;80(1):75-84. doi: 10.1016/j.clpt.2006.03.010. [PubMed:16815319]
  3. Flockhart Table of Drug Interactions [Link]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inducer
General Function
Steroid binding
Specific Function
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform glucuronidates bilirubin IX-alpha to form both the...
Gene Name
UGT1A1
Uniprot ID
P22309
Uniprot Name
UDP-glucuronosyltransferase 1-1
Molecular Weight
59590.91 Da
References
  1. Ellis E, Wagner M, Lammert F, Nemeth A, Gumhold J, Strassburg CP, Kylander C, Katsika D, Trauner M, Einarsson C, Marschall HU: Successful treatment of severe unconjugated hyperbilirubinemia via induction of UGT1A1 by rifampicin. J Hepatol. 2006 Jan;44(1):243-5. Epub 2005 Oct 27. [PubMed:16288819]
  2. Jemnitz K, Lengyel G, Vereczkey L: In vitro induction of bilirubin conjugation in primary rat hepatocyte culture. Biochem Biophys Res Commun. 2002 Feb 15;291(1):29-33. [PubMed:11829457]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inducer
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
References
  1. Edwards RJ, Price RJ, Watts PS, Renwick AB, Tredger JM, Boobis AR, Lake BG: Induction of cytochrome P450 enzymes in cultured precision-cut human liver slices. Drug Metab Dispos. 2003 Mar;31(3):282-8. [PubMed:12584154]
  2. Park GJ, Bae SH, Park WS, Han S, Park MH, Shin SH, Shin YG, Yim DS: Drug-drug interaction of microdose and regular-dose omeprazole with a CYP2C19 inhibitor and inducer. Drug Des Devel Ther. 2017 Mar 30;11:1043-1053. doi: 10.2147/DDDT.S131797. eCollection 2017. [PubMed:28408803]
  3. Ridtitid W, Wongnawa M, Mahatthanatrakul W, Punyo J, Sunbhanich M: Rifampin markedly decreases plasma concentrations of praziquantel in healthy volunteers. Clin Pharmacol Ther. 2002 Nov;72(5):505-13. doi: 10.1067/mcp.2002.129319. [PubMed:12426514]
  4. Clin-Info. (2006). In Compendium of Pharmaceuticals and Specialties: The Canadian Drug Reference for Health Professionals (pp. L57). Canadian Pharmacists Association. [ISBN:1-894402-22-7]
  5. Rifampicin [Link]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inducer
General Function
Steroid hydroxylase activity
Specific Function
Exhibits a high coumarin 7-hydroxylase activity. Can act in the hydroxylation of the anti-cancer drugs cyclophosphamide and ifosphamide. Competent in the metabolic activation of aflatoxin B1. Const...
Gene Name
CYP2A6
Uniprot ID
P11509
Uniprot Name
Cytochrome P450 2A6
Molecular Weight
56501.005 Da
References
  1. Edwards RJ, Price RJ, Watts PS, Renwick AB, Tredger JM, Boobis AR, Lake BG: Induction of cytochrome P450 enzymes in cultured precision-cut human liver slices. Drug Metab Dispos. 2003 Mar;31(3):282-8. [PubMed:12584154]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inducer
General Function
Steroid hydroxylase activity
Specific Function
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic ...
Gene Name
CYP2E1
Uniprot ID
P05181
Uniprot Name
Cytochrome P450 2E1
Molecular Weight
56848.42 Da
References
  1. Huang R, Okuno H, Takasu M, Shiozaki Y, Inoue K: Protective effect of rifampicin against acute liver injury induced by carbon tetrachloride in mice. Jpn J Pharmacol. 1995 Dec;69(4):325-34. [PubMed:8786635]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inducer
General Function
Monooxygenase activity
Specific Function
Exhibits low testosterone 6-beta-hydroxylase activity.
Gene Name
CYP3A43
Uniprot ID
Q9HB55
Uniprot Name
Cytochrome P450 3A43
Molecular Weight
57669.21 Da
References
  1. Gellner K, Eiselt R, Hustert E, Arnold H, Koch I, Haberl M, Deglmann CJ, Burk O, Buntefuss D, Escher S, Bishop C, Koebe HG, Brinkmann U, Klenk HP, Kleine K, Meyer UA, Wojnowski L: Genomic organization of the human CYP3A locus: identification of a new, inducible CYP3A gene. Pharmacogenetics. 2001 Mar;11(2):111-21. [PubMed:11266076]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inducer
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A7
Uniprot ID
P24462
Uniprot Name
Cytochrome P450 3A7
Molecular Weight
57525.03 Da
References
  1. Usui T, Saitoh Y, Komada F: Induction of CYP3As in HepG2 cells by several drugs. Association between induction of CYP3A4 and expression of glucocorticoid receptor. Biol Pharm Bull. 2003 Apr;26(4):510-7. doi: 10.1248/bpb.26.510. [PubMed:12673034]
  2. FDA Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers [Link]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Retinoic acid binding
Specific Function
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform has specificity for phenols. Isoform 2 lacks trans...
Gene Name
UGT1A9
Uniprot ID
O60656
Uniprot Name
UDP-glucuronosyltransferase 1-9
Molecular Weight
59940.495 Da
References
  1. Soars MG, Petullo DM, Eckstein JA, Kasper SC, Wrighton SA: An assessment of udp-glucuronosyltransferase induction using primary human hepatocytes. Drug Metab Dispos. 2004 Jan;32(1):140-8. doi: 10.1124/dmd.32.1.140. [PubMed:14709631]
  2. Kasichayanula S, Liu X, Griffen SC, Lacreta FP, Boulton DW: Effects of rifampin and mefenamic acid on the pharmacokinetics and pharmacodynamics of dapagliflozin. Diabetes Obes Metab. 2013 Mar;15(3):280-3. doi: 10.1111/dom.12024. Epub 2012 Nov 19. [PubMed:23061428]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inducer
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A5
Uniprot ID
P20815
Uniprot Name
Cytochrome P450 3A5
Molecular Weight
57108.065 Da
References
  1. Burk O, Koch I, Raucy J, Hustert E, Eichelbaum M, Brockmoller J, Zanger UM, Wojnowski L: The induction of cytochrome P450 3A5 (CYP3A5) in the human liver and intestine is mediated by the xenobiotic sensors pregnane X receptor (PXR) and constitutively activated receptor (CAR). J Biol Chem. 2004 Sep 10;279(37):38379-85. doi: 10.1074/jbc.M404949200. Epub 2004 Jul 12. [PubMed:15252010]
  2. FDA Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers [Link]

Carriers

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Ligand
General Function
Toxic substance binding
Specific Function
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
Gene Name
ALB
Uniprot ID
P02768
Uniprot Name
Serum albumin
Molecular Weight
69365.94 Da
References
  1. Baneres-Roquet F, Gualtieri M, Villain-Guillot P, Pugniere M, Leonetti JP: Use of a surface plasmon resonance method to investigate antibiotic and plasma protein interactions. Antimicrob Agents Chemother. 2009 Apr;53(4):1528-31. doi: 10.1128/AAC.00971-08. Epub 2009 Jan 21. [PubMed:19164148]
Kind
Protein group
Organism
Humans
Pharmacological action
Unknown
Actions
Ligand
General Function
Not Available
Specific Function
Functions as transport protein in the blood stream. Binds various ligands in the interior of its beta-barrel domain. Also binds synthetic drugs and influences their distribution and availability in...

Components:
References
  1. Baneres-Roquet F, Gualtieri M, Villain-Guillot P, Pugniere M, Leonetti JP: Use of a surface plasmon resonance method to investigate antibiotic and plasma protein interactions. Antimicrob Agents Chemother. 2009 Apr;53(4):1528-31. doi: 10.1128/AAC.00971-08. Epub 2009 Jan 21. [PubMed:19164148]

Transporters

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inducer
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Geick A, Eichelbaum M, Burk O: Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J Biol Chem. 2001 May 4;276(18):14581-7. Epub 2001 Jan 31. [PubMed:11297522]
  2. Schuetz EG, Beck WT, Schuetz JD: Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. Mol Pharmacol. 1996 Feb;49(2):311-8. [PubMed:8632764]
  3. Greiner B, Eichelbaum M, Fritz P, Kreichgauer HP, von Richter O, Zundler J, Kroemer HK: The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J Clin Invest. 1999 Jul;104(2):147-53. doi: 10.1172/JCI6663. [PubMed:10411543]
  4. Fardel O, Lecureur V, Loyer P, Guillouzo A: Rifampicin enhances anti-cancer drug accumulation and activity in multidrug-resistant cells. Biochem Pharmacol. 1995 May 11;49(9):1255-60. [PubMed:7763306]
  5. Kuypers DR, Verleden G, Naesens M, Vanrenterghem Y: Drug interaction between mycophenolate mofetil and rifampin: possible induction of uridine diphosphate-glucuronosyltransferase. Clin Pharmacol Ther. 2005 Jul;78(1):81-8. [PubMed:16003296]
  6. Gurley BJ, Barone GW, Williams DK, Carrier J, Breen P, Yates CR, Song PF, Hubbard MA, Tong Y, Cheboyina S: Effect of milk thistle (Silybum marianum) and black cohosh (Cimicifuga racemosa) supplementation on digoxin pharmacokinetics in humans. Drug Metab Dispos. 2006 Jan;34(1):69-74. Epub 2005 Oct 12. [PubMed:16221754]
  7. Chen J, Raymond K: Roles of rifampicin in drug-drug interactions: underlying molecular mechanisms involving the nuclear pregnane X receptor. Ann Clin Microbiol Antimicrob. 2006 Feb 15;5:3. [PubMed:16480505]
  8. Lamba J, Strom S, Venkataramanan R, Thummel KE, Lin YS, Liu W, Cheng C, Lamba V, Watkins PB, Schuetz E: MDR1 genotype is associated with hepatic cytochrome P450 3A4 basal and induction phenotype. Clin Pharmacol Ther. 2006 Apr;79(4):325-38. Epub 2006 Feb 20. [PubMed:16580901]
  9. Huang R, Murry DJ, Kolwankar D, Hall SD, Foster DR: Vincristine transcriptional regulation of efflux drug transporters in carcinoma cell lines. Biochem Pharmacol. 2006 Jun 14;71(12):1695-704. Epub 2006 Apr 18. [PubMed:16620787]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent uptake of organic anions such as 17-beta-glucuronosyl estradiol, taurocholate, triiodothyronine (T3), leukotriene C4, dehydroepiandrosterone sulfate (DHEAS), methotre...
Gene Name
SLCO1B3
Uniprot ID
Q9NPD5
Uniprot Name
Solute carrier organic anion transporter family member 1B3
Molecular Weight
77402.175 Da
References
  1. Cui Y, Konig J, Leier I, Buchholz U, Keppler D: Hepatic uptake of bilirubin and its conjugates by the human organic anion transporter SLC21A6. J Biol Chem. 2001 Mar 30;276(13):9626-30. Epub 2000 Dec 27. [PubMed:11134001]
  2. Vavricka SR, Van Montfoort J, Ha HR, Meier PJ, Fattinger K: Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver. Hepatology. 2002 Jul;36(1):164-72. [PubMed:12085361]
  3. Cui Y, Konig J, Keppler D: Vectorial transport by double-transfected cells expressing the human uptake transporter SLC21A8 and the apical export pump ABCC2. Mol Pharmacol. 2001 Nov;60(5):934-43. [PubMed:11641421]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Transporter activity
Specific Function
Mediates export of organic anions and drugs from the cytoplasm. Mediates ATP-dependent transport of glutathione and glutathione conjugates, leukotriene C4, estradiol-17-beta-o-glucuronide, methotre...
Gene Name
ABCC1
Uniprot ID
P33527
Uniprot Name
Multidrug resistance-associated protein 1
Molecular Weight
171589.5 Da
References
  1. Courtois A, Payen L, Vernhet L, de Vries EG, Guillouzo A, Fardel O: Inhibition of multidrug resistance-associated protein (MRP) activity by rifampicin in human multidrug-resistant lung tumor cells. Cancer Lett. 1999 May 3;139(1):97-104. [PubMed:10408915]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates sodium-independent multispecific organic anion transport. Transport of prostaglandin E2, prostaglandin F2, tetracycline, bumetanide, estrone sulfate, glutarate, dehydroepiandrosterone sulf...
Gene Name
SLC22A7
Uniprot ID
Q9Y694
Uniprot Name
Solute carrier family 22 member 7
Molecular Weight
60025.025 Da
References
  1. Sekine T, Cha SH, Tsuda M, Apiwattanakul N, Nakajima N, Kanai Y, Endou H: Identification of multispecific organic anion transporter 2 expressed predominantly in the liver. FEBS Lett. 1998 Jun 12;429(2):179-82. [PubMed:9650585]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent uptake of organic anions such as pravastatin, taurocholate, methotrexate, dehydroepiandrosterone sulfate, 17-beta-glucuronosyl estradiol, estrone sulfate, prostagland...
Gene Name
SLCO1B1
Uniprot ID
Q9Y6L6
Uniprot Name
Solute carrier organic anion transporter family member 1B1
Molecular Weight
76447.99 Da
References
  1. Cui Y, Konig J, Leier I, Buchholz U, Keppler D: Hepatic uptake of bilirubin and its conjugates by the human organic anion transporter SLC21A6. J Biol Chem. 2001 Mar 30;276(13):9626-30. Epub 2000 Dec 27. [PubMed:11134001]
  2. Vavricka SR, Van Montfoort J, Ha HR, Meier PJ, Fattinger K: Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver. Hepatology. 2002 Jul;36(1):164-72. [PubMed:12085361]
  3. Tirona RG, Leake BF, Wolkoff AW, Kim RB: Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation. J Pharmacol Exp Ther. 2003 Jan;304(1):223-8. [PubMed:12490595]
  4. Sharma P, Holmes VE, Elsby R, Lambert C, Surry D: Validation of cell-based OATP1B1 assays to assess drug transport and the potential for drug-drug interaction to support regulatory submissions. Xenobiotica. 2010 Jan;40(1):24-37. doi: 10.3109/00498250903351013. [PubMed:19919292]
  5. Anderson MS, Cote J, Liu Y, Stypinski D, Auger P, Hohnstein A, Rasmussen S, Johnson-Levonas AO, Gutstein DE: Effects of Rifampin, a potent inducer of drug-metabolizing enzymes and an inhibitor of OATP1B1/3 transport, on the single dose pharmacokinetics of anacetrapib. J Clin Pharmacol. 2013 Jul;53(7):746-52. doi: 10.1002/jcph.97. Epub 2013 May 14. [PubMed:23670789]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inducer
General Function
Organic anion transmembrane transporter activity
Specific Function
May act as an inducible transporter in the biliary and intestinal excretion of organic anions. Acts as an alternative route for the export of bile acids and glucuronides from cholestatic hepatocyte...
Gene Name
ABCC3
Uniprot ID
O15438
Uniprot Name
Canalicular multispecific organic anion transporter 2
Molecular Weight
169341.14 Da
References
  1. Teng S, Jekerle V, Piquette-Miller M: Induction of ABCC3 (MRP3) by pregnane X receptor activators. Drug Metab Dispos. 2003 Nov;31(11):1296-9. [PubMed:14570758]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inducer
General Function
Organic anion transmembrane transporter activity
Specific Function
Acts as a multispecific organic anion pump which can transport nucleotide analogs.
Gene Name
ABCC5
Uniprot ID
O15440
Uniprot Name
Multidrug resistance-associated protein 5
Molecular Weight
160658.8 Da
References
  1. Schrenk D, Baus PR, Ermel N, Klein C, Vorderstemann B, Kauffmann HM: Up-regulation of transporters of the MRP family by drugs and toxins. Toxicol Lett. 2001 Mar 31;120(1-3):51-7. [PubMed:11323161]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent transport of organic anions such as taurocholate, the prostaglandins PGD2, PGE1, PGE2, leukotriene C4, thromboxane B2 and iloprost.
Gene Name
SLCO2B1
Uniprot ID
O94956
Uniprot Name
Solute carrier organic anion transporter family member 2B1
Molecular Weight
76709.98 Da
References
  1. Vavricka SR, Van Montfoort J, Ha HR, Meier PJ, Fattinger K: Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver. Hepatology. 2002 Jul;36(1):164-72. [PubMed:12085361]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent transport of organic anions such as sulfobromophthalein (BSP) and conjugated (taurocholate) and unconjugated (cholate) bile acids (By similarity). Selectively inhibit...
Gene Name
SLCO1A2
Uniprot ID
P46721
Uniprot Name
Solute carrier organic anion transporter family member 1A2
Molecular Weight
74144.105 Da
References
  1. Vavricka SR, Van Montfoort J, Ha HR, Meier PJ, Fattinger K: Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver. Hepatology. 2002 Jul;36(1):164-72. [PubMed:12085361]
  2. Fattinger K, Cattori V, Hagenbuch B, Meier PJ, Stieger B: Rifamycin SV and rifampicin exhibit differential inhibition of the hepatic rat organic anion transporting polypeptides, Oatp1 and Oatp2. Hepatology. 2000 Jul;32(1):82-6. [PubMed:10869292]
  3. Shitara Y, Sugiyama D, Kusuhara H, Kato Y, Abe T, Meier PJ, Itoh T, Sugiyama Y: Comparative inhibitory effects of different compounds on rat oatpl (slc21a1)- and Oatp2 (Slc21a5)-mediated transport. Pharm Res. 2002 Feb;19(2):147-53. [PubMed:11883641]
  4. van Montfoort JE, Stieger B, Meijer DK, Weinmann HJ, Meier PJ, Fattinger KE: Hepatic uptake of the magnetic resonance imaging contrast agent gadoxetate by the organic anion transporting polypeptide Oatp1. J Pharmacol Exp Ther. 1999 Jul;290(1):153-7. [PubMed:10381771]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Transporter activity
Specific Function
Involved in the ATP-dependent secretion of bile salts into the canaliculus of hepatocytes.
Gene Name
ABCB11
Uniprot ID
O95342
Uniprot Name
Bile salt export pump
Molecular Weight
146405.83 Da
References
  1. Byrne JA, Strautnieks SS, Mieli-Vergani G, Higgins CF, Linton KJ, Thompson RJ: The human bile salt export pump: characterization of substrate specificity and identification of inhibitors. Gastroenterology. 2002 Nov;123(5):1649-58. [PubMed:12404239]
  2. Noe J, Hagenbuch B, Meier PJ, St-Pierre MV: Characterization of the mouse bile salt export pump overexpressed in the baculovirus system. Hepatology. 2001 May;33(5):1223-31. [PubMed:11343252]
  3. Stieger B, Fattinger K, Madon J, Kullak-Ublick GA, Meier PJ: Drug- and estrogen-induced cholestasis through inhibition of the hepatocellular bile salt export pump (Bsep) of rat liver. Gastroenterology. 2000 Feb;118(2):422-30. [PubMed:10648470]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inducer
General Function
Organic anion transmembrane transporter activity
Specific Function
Mediates hepatobiliary excretion of numerous organic anions. May function as a cellular cisplatin transporter.
Gene Name
ABCC2
Uniprot ID
Q92887
Uniprot Name
Canalicular multispecific organic anion transporter 1
Molecular Weight
174205.64 Da
References
  1. Kauffmann HM, Pfannschmidt S, Zoller H, Benz A, Vorderstemann B, Webster JI, Schrenk D: Influence of redox-active compounds and PXR-activators on human MRP1 and MRP2 gene expression. Toxicology. 2002 Feb 28;171(2-3):137-46. [PubMed:11836020]
  2. Fromm MF, Kauffmann HM, Fritz P, Burk O, Kroemer HK, Warzok RW, Eichelbaum M, Siegmund W, Schrenk D: The effect of rifampin treatment on intestinal expression of human MRP transporters. Am J Pathol. 2000 Nov;157(5):1575-80. [PubMed:11073816]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one ...
Gene Name
SLC22A6
Uniprot ID
Q4U2R8
Uniprot Name
Solute carrier family 22 member 6
Molecular Weight
61815.78 Da
References
  1. OAT1 and OAT3 (organic anion transporters 1 and 3) [Link]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Plays an important role in the excretion/detoxification of endogenous and exogenous organic anions, especially from the brain and kidney. Involved in the transport basolateral of steviol, fexofenad...
Gene Name
SLC22A8
Uniprot ID
Q8TCC7
Uniprot Name
Solute carrier family 22 member 8
Molecular Weight
59855.585 Da
References
  1. OAT1 and OAT3 (organic anion transporters 1 and 3) [Link]

Drug created on June 13, 2005 07:24 / Updated on December 14, 2019 00:50